Dr. Reddy's Laboratories ... (RDY)
| Bid | 13.03 |
| Market Cap | 11.01B |
| Revenue (ttm) | 311.31B |
| Net Income (ttm) | 53.68B |
| EPS (ttm) | 0.74 |
| PE Ratio (ttm) | 17.86 |
| Forward PE | 0.19 |
| Analyst | Buy |
| Ask | 13.45 |
| Volume | 2,524,297 |
| Avg. Volume (20D) | 2,087,500 |
| Open | 12.84 |
| Previous Close | 12.71 |
| Day's Range | 12.78 - 13.22 |
| 52-Week Range | 12.26 - 16.89 |
| Beta | 0.48 |
About RDY
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finish...
Analyst Forecast
According to 1 analyst ratings, the average rating for RDY stock is "Buy." The 12-month stock price forecast is $17, which is an increase of 28.64% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago · seekingalpha.com
Dr. Reddy's Laboratories Limited (RDY) Q3 2025 Earnings Call TranscriptDr. Reddy's Laboratories Limited (NYSE:RDY ) Q3 2025 Earnings Conference Call January 23, 2025 9:00 AM ET Company Participants Richa Periwal – Head-Investor Relations and Analytics Erez Israeli – Chie...
